TY - JOUR
T1 - Refining the diagnoses of inattention and overactivity syndromes
T2 - A reanalysis of the Multimodal Treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder
AU - Santosh, Paramala J.
AU - Taylor, E.
AU - Swanson, J.
AU - Wigal, T.
AU - Chuang, S.
AU - Davies, M.
AU - Greenhill, L.
AU - Newcorn, J.
AU - Arnold, L. E.
AU - Jensen, P.
AU - Vitiello, B.
AU - Elliott, G.
AU - Hinshaw, S.
AU - Hechtman, L.
AU - Abikoff, H.
AU - Pelham, W.
AU - Hoza, B.
AU - Molina, B.
AU - Wells, K.
AU - Epstein, J.
AU - Posner, M.
N1 - Funding Information:
The study was funded by the Sackler Foundation, and Professor Taylor's contribution was with support from the Medical Research Council.
PY - 2005/12
Y1 - 2005/12
N2 - There are large differences between nations in the diagnosis and management of children with marked impulsiveness and inattention. The differences extend to the names and definitions of disorder and the extent to which medication should be used. This paper uses data from a large randomized clinical trial of pharmacological and psychosocial treatments, conducted in North America, to clarify its implications for other parts of the world. A diagnostic algorithm was applied to 579 children, diagnosed with ADHD-Combined Type in the MTA trial, to generate the ICD-10 diagnosis of 'hyperkinetic disorder' (HD); only a quarter met these more stringent criteria. HD was a moderator of treatment response. The superiority of medication to behavioral treatment was greater for children with HD. Children with ADHD but not HD also showed some improvement with medication. The results provide evidence for the validity of HD as a subgroup of those presenting ADHD; and suggest that treatment with stimulants is a high priority in children with HD. Results also suggest that some children with other forms of ADHD will respond better to medication than to psychosocial intervention, and therefore that European guidelines should extend their indications.
AB - There are large differences between nations in the diagnosis and management of children with marked impulsiveness and inattention. The differences extend to the names and definitions of disorder and the extent to which medication should be used. This paper uses data from a large randomized clinical trial of pharmacological and psychosocial treatments, conducted in North America, to clarify its implications for other parts of the world. A diagnostic algorithm was applied to 579 children, diagnosed with ADHD-Combined Type in the MTA trial, to generate the ICD-10 diagnosis of 'hyperkinetic disorder' (HD); only a quarter met these more stringent criteria. HD was a moderator of treatment response. The superiority of medication to behavioral treatment was greater for children with HD. Children with ADHD but not HD also showed some improvement with medication. The results provide evidence for the validity of HD as a subgroup of those presenting ADHD; and suggest that treatment with stimulants is a high priority in children with HD. Results also suggest that some children with other forms of ADHD will respond better to medication than to psychosocial intervention, and therefore that European guidelines should extend their indications.
KW - Attention deficit\hyperactivity disorder
KW - Hyperkinetic disorder
KW - Nosology
KW - Stimulant medication
KW - Treatment guidelines
UR - http://www.scopus.com/inward/record.url?scp=29744456053&partnerID=8YFLogxK
U2 - 10.1016/j.cnr.2005.09.010
DO - 10.1016/j.cnr.2005.09.010
M3 - Article
AN - SCOPUS:29744456053
SN - 1566-2772
VL - 5
SP - 307
EP - 314
JO - Clinical Neuroscience Research
JF - Clinical Neuroscience Research
IS - 5-6
ER -